Do Diabetics Take Ozempic? GLP-1 Use in Diabetes & Genetic Ins...

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, diabetics do take Ozempic and other GLP-1 receptor agonists as a core treatment for type 2 diabetes. GLP-1 medications reduce fasting blood glucose by approximately 1.5–2% HbA1c in clinical trials, with some patients achieving even greater reductions depending on baseline glucose control and individual metabolism.

GLP-1 therapy has expanded far beyond diabetes into weight management, cardiovascular protection, and metabolic health. However, not every GLP-1 medication works equally well for every person. Understanding your genetic predispositions in key metabolic pathways can help inform a more personalized conversation with your provider about which formulation and dosing strategy may align best with your biology.

How GLP-1 Medications Work in Type 2 Diabetes

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. In type 2 diabetes, these medications stimulate insulin secretion in response to meals, reduce glucagon release, and slow gastric emptying—all mechanisms that lower postprandial and fasting glucose levels.

Semaglutide (Ozempic for diabetes; Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes; Zepbound for weight loss) are the most widely prescribed GLP-1s. Both are available in injectable and oral formulations through various manufacturers and compounding pharmacies, offering flexibility in administration route and dosing schedules.

GLP-1 Efficacy, Genetics, and Individual Response Variation

Clinical trials show that GLP-1 efficacy varies significantly across patients. Some individuals achieve robust HbA1c reductions and weight loss, while others experience modest improvements. This variation reflects differences in baseline insulin secretion capacity, insulin sensitivity, gastrointestinal motility, and genetic variation in the GLP-1 receptor and related metabolic pathways.

Genetic Factor	Gene/Variant	Potential Relevance to GLP-1 Response
GLP-1 Receptor Signaling	GLP1R rs6923761	May influence GLP-1 receptor function and medication response sensitivity
GIPR Pathway Co-activation	GIPR rs1800437	Relevant to dual GLP-1/GIP compounds; associated with glucose metabolism
Appetite & Energy Regulation	MC4R rs17782313	Related to leptin signaling; may influence satiety and weight loss response
Fat Mass & Metabolic Rate	FTO rs9939609	Associated with baseline obesity risk and metabolic flexibility

Branded vs. Compounded GLP-1 Options: What You Should Know

Branded GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved and manufactured under strict pharmaceutical standards. Compounded GLP-1s from licensed 503A pharmacies offer an alternative for patients seeking lower cost, faster access, or flexibility in dosing schedules. Both require a prescription and ongoing medical supervision.

Compounded semaglutide and tirzepatide are not identical to their branded counterparts but follow the same active pharmaceutical ingredient formulations. Cost typically ranges from $149/mo monthly for compounded options versus $900–$1,400 for branded medications. Your provider should evaluate which option aligns with your clinical needs, insurance coverage, and treatment goals.

Who Should Take GLP-1 Medications: Safety, Eligibility, and Provider Guidance

GLP-1s are indicated for type 2 diabetes with or without obesity, cardiovascular disease, or chronic kidney disease. They are contraindicated in type 1 diabetes, personal history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2. Pregnancy, breastfeeding, and severe gastrointestinal disease require careful provider assessment before initiation.

Common side effects include nausea, vomiting, constipation, and diarrhea—typically mild and transient during dose escalation. Rare but serious concerns include pancreatitis, gallbladder disease, and retinopathy progression in advanced diabetic patients. A qualified healthcare provider should assess your full medical history, medications, and comorbidities before starting any GLP-1 therapy and monitor you regularly during treatment.

The Role of Genetic Testing in Personalizing Your GLP-1 Conversation

Genetic variation in the GLP-1 receptor and related metabolic pathways exists across all populations. Understanding your predispositions in these pathways may help provide context for why certain formulations or dosing strategies might align better with your individual biology, supporting a more informed discussion with your provider.

PlexusDx's Precision Peptide Genetic Test reveals your predispositions in key GLP-1 signaling genes (GLP1R, GIPR), appetite regulation (MC4R), and metabolic flexibility (FTO). This information does not predict your exact medication response but can help you and your provider make more personalized treatment decisions aligned with your genetic landscape.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic insights focus specifically on peptide pathway predispositions—how your genes influence GLP-1 receptor sensitivity, dual GLP-1/GIP responsiveness, appetite signaling, and metabolic flexibility. This may help provide context for understanding why you might respond differently to GLP-1 therapy than someone else, supporting a more personalized conversation with your provider.

The Precision Peptide Genetic Test examines variants in GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609. These predispositions reveal your genetic blueprint in metabolic and appetite regulation—not your exact medication response. Your results should always be interpreted with a qualified healthcare provider who understands your full clinical picture.

If you are considering GLP-1 therapy for diabetes or weight management, understanding your genetic predispositions may help you ask more targeted questions about which formulation (semaglutide vs. tirzepatide), route (injection vs. oral), and dosing schedule align best with your biology. Pairing genetic context with your provider's clinical judgment leads to more intentional, personalized treatment decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.